Dr. Yuan Zhi joined Shenzhen BORUI as Vice General Manager
Dr. Yuan Zhi has more than 30 years of working experiences in the field of bioanalysis and relating fields (discovery and development of small / macromolecular drugs), familiar with domestic and international bioanalysis regulations, and has rich practical experience in the fields of bioanalysis, biological sample processing, laboratory management, etc.
In 1987, Dr. Yuan Zhi received his Ph.D. in physical chemistry from the Department of chemistry, University of Oregon, USA, and then accepted formal clinical chemistry training in the Department of Laboratory Medicine and Pathology of Mayo Clinic, Rochester, Minnesota, including clinical drug monitoring and drug of abuse screening and confirmation in clinical toxicology laboratory, also including the development, validation and implementation of the bioanalytical method, which opened the career path of bioanalysis.
Developed, validated and implemented by Dr. Yuan Zhi in Mayo Clinic, a GC-MS based analytical method for screening / confirmation of barbiturates can simultaneously identify, confirm and quantitatively analyze nine barbiturates. This method performed well in the quality control program of Reference Labs, and won the research award of the 46th annual meeting of the American Association of Clinical Chemistry (AACC) in 1994 and the Richard Marshall Education Award of the Chinese and western part of AACC. After that, Dr. Yuan Zhi took the lead in developing and improving the SPE method for penicillin antibiotics in the school of pharmacy, University of Minnesota, USA, greatly improving the sensitivity and reliability of the correlation analysis method based on liquid chromatography.
In addition, Dr. Yuan Zhi has been engaged in the development, validation and implementation of bioanalytical methods (mainly liquid chromatography, liquid chromatography-mass spectrometry and other technologies) in two well-known CRO companies PPD and tandem labs in the United States. In recent years, Dr. Yuan Zhi has further expanded his research field and entered the development and validation of macromolecular bioanalysis (LBA) method and immunogenicity (ADA) test method to support the development of macromolecular biological drugs.
Dr. Wang Jianhua, general manager of Shenzhen BORUI, said that Dr. Yuan Zhi is a person with rich experiences in the industry, and we are very happy to invite Dr. Yuan Zhi to join Shenzhen BORUI to jointly promote the innovative drug R&D. Dr. Yuan Zhi's rich theoretical and practical experience in bioanalysis will help Shenzhen BORUI become a pearl in the field of innovative drug R&D services in Great Bay Area.